Photo Credit: Nemes Laszlo
The following is a summary of “Impact of Cytogenetic Abnormalities, Induction and Maintenance Regimens on Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: A Decade-Long Real-World Experience,” published in the December 2023 issue of Hematology by Thurlapati et al.
Researchers started a retrospective study to assess the impact of high-risk cytogenetic abnormalities (HRCAs) on outcomes after high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT) for newly diagnosed multiple myeloma (NDMM) patients.
They involved 449 patients with NDMM who received HDT-ASCT (February 2012 and August 2022). HRCAs, comprising deletion 17p, t(14;16), t(4;14), and amplification 1q, were assessed. Kaplan-Meier estimator was employed to analyze survival outcomes, including PFS and OS.
The results showed a median follow-up of 29 (1 – 128) months. Patients with HRCAs had a lower overall response rate than those with standard-risk cytogenetics (90% vs. 96%; P=0.01). Patients with HRCAs experienced inferior PFS (29 vs. 58 months; P<0.001) but no significant difference in OS (70 months vs. not reached; P=0.13).
Investigators concluded that HRCAs, non-lenalidomide maintenance, and older age were linked to worse PFS; only non-lenalidomide maintenance was related to worse OS.
Source: thejh.org/index.php/jh/article/view/1201
